Innovative NeuroTechnologies, Inc

Innovative NeuroTechnologies, Inc. (INT) is primarily an early-stage clinical development biotechnology company that seeks novel therapeutic solutions (i.e., biopharmaceuticals, stem cells) for major human central nervous system (CNS) disorders, particularly in the area of neurodegeneration.

The Company presently focuses its main efforts on Alzheimer's disease (AD), with interest in therapeutic solutions for Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Huntington’s disease (HD), frontotemporal lobar dementias (FTLDs or Picks’s disease), stroke, and multiple sclerosis (MS). These are typically fatal neurodegenerative disorders that are currently untreatable and share many characteristics, which make them particularly amenable to INT's expertise and employed technologies.